• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OS Therapies Incorporated

    10/31/25 4:37:31 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    S-8 1 ea0262504-s8_osthera.htm REGISTRATION STATEMENT

    As filed with the U.S. Securities and Exchange Commission on October 31, 2025

    Registration No. 333-                 

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    OS THERAPIES INCORPORATED
    (Exact name of registrant as specified in its charter)

     

    Delaware   82-5118368
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         

    115 Pullman Crossing Road, Suite 103

    Grasonville, Maryland

      21638
    (Address of Principal Executive Offices)   (Zip Code)

     

    2023 Incentive Compensation Plan
    (Full title of the plan)

     

    Paul A. Romness, MPH
    President and Chief Executive Officer
    OS Therapies Incorporated
    115 Pullman Crossing Road, Suite #103
    Grasonville, Maryland 21638
    (410) 297-7793
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Spencer G. Feldman, Esq.
    Olshan Frome Wolosky LLP
    1325 Avenue of the Americas, 15th Floor
    New York, New York 10019
    (212) 451-2300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer   ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by OS Therapies Incorporated (the “Company,” “we,” “us” and “our”) for the purpose of registering an additional 6,000,000 shares of our common stock under the Company’s 2023 Incentive Compensation Plan, as amended. The Company’s Registration Statement on Form S-8 (File No. 333-284242) filed with the Securities and Exchange Commission (the “SEC”) on January 13, 2025 is incorporated by reference herein.

     

     

     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information required by Item 1 and Item 2 of Part I of Form S-8 will be sent or given to employees as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents need not be filed with the SEC either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in the registration statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by us with the SEC under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items):

     

    ●Our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025;

     

    ●Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on May 15, 2025 and August 18, 2025, respectively;

     

    ●Our Current Reports on Form 8-K (only to the extent “filed” and not “furnished”), filed with the SEC on January 3, 2025, January 14, 2025, January 15, 2025, January 29, 2025, April 2, 2025, April 9, 2025, April 15, 2025, June 24, 2025, June 27, 2025, July 14, 2025, August 15, 2025, August 26, 2025, September 2, 2025, September 30, 2025, October 17, 2025 and October 21, 2025; and

     

    ●The description of our registered securities contained in Exhibit 4.9 to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or reports filed for the purpose of updating this description.

     

    All documents filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document that is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

     

    We have adopted provisions in our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

     

    ●any breach of the director’s duty of loyalty to us or our stockholders;

     

    ●any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

    ●any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

     

    ●any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

     

    In addition, our bylaws provide that:

     

    ●we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

     

    ●we will advance reasonable expenses, including attorneys’ fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions

     

    We have entered into separate indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, we will agree in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

     

    II-2

     

     

    We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

     

    Delaware Law

     

    Section 102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification will be made with respect to any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court will deem proper.

     

    Third Amended and Restated Certificate of Incorporation

     

    Our third amended and restated certificate of incorporation provides that we are authorized to provide indemnification and advancement of expenses to our directors, officers and certain other covered persons to the fullest extent permitted by the DGCL. Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions will not eliminate or limit the liability of any of our directors for:

     

    ●for any breach of the director’s duty of loyalty to us or our stockholders;

     

    ●for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

    ●for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or

     

    ●for any transaction from which the director derived an improper personal benefit.

     

    II-3

     

     

    In addition, our third amended and restated certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, other than an action by or in the right of us, by reason of the fact that such person is or was a director or officer of the Company or is or was serving at the request of the Company as a director, officer, employee, general partner, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), against all expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

     

    Indemnification Agreements

     

    We have entered into separate indemnification agreements with each of our directors and executive officers. These indemnification agreements require us, among other things, to indemnify our directors and officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

     

    We maintain general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on their acts or omissions committed in their capacities as directors or officers.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit
    number
      Description
    3.1   Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.(1)
    3.2   Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.(2)
    3.3*   Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.
    3.3   Amended and Restated Bylaws of OS Therapies Incorporated.(1)
    3.4   Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated.(3)
    4.1   OS Therapies Incorporated 2023 Incentive Compensation Plan, as amended.(4)
    5.1*   Opinion of Olshan Frome Wolosky LLP, as to the legality of the common stock.
    23.1*   Consent of MaloneBailey, LLP, independent registered public accounting firm.
    23.2*   Consent of Olshan Frome Wolosky LLP (included in the opinion filed as Exhibit 5.1).
    24   Power of Attorney (set forth on signature page of the Registration Statement).
    107*   Calculation of Filing Fee Table.

     

     

    (1)Incorporated herein by reference to the Company’s Registration Statement on Form S-1 filed May 30, 2024 (File No. 333-279839).
    (2)Incorporated herein by reference to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed June 7, 2024 (File No. 333-279839).
    (3)Incorporated herein by reference to the Company’s Current Report on Form 8-K filed August 15, 2025.
    (4)Incorporated herein by reference to the Company’s Current Report on Form 8-K filed October 21, 2025.
    *Filed herewith.

     

    II-4

     

     

    Item 9. Undertakings.

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post−effective amendment to this registration statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that for the purpose of determining any liability under the Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act, and will be governed by the final adjudication of such issue.

     

    II-5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Grasonville, State of Maryland on October 31, 2025.

     

      OS THERAPIES INCORPORATED
       
      By:

    /s/ Paul A. Romness, MPH

        Paul A. Romness, MPH
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of OS Therapies Incorporated hereby severally constitute and appoint Paul A. Romness, MPH and Christopher P. Acevedo, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Paul A. Romness, MPH   Chairman, President and Chief Executive Officer   October 31, 2025
    Paul A. Romness, MPH   (principal executive officer)    
             
    /s/ Christopher P. Acevedo   Chief Financial Officer   October 31, 2025
    Christopher P. Acevedo   (principal financial officer and principal accounting officer)    
             
    /s/ John Ciccio   Director   October 31, 2025
    John Ciccio        
             
    /s/ Avril McKean Dieser   Director   October 31, 2025
    Avril McKean Dieser        
             
    /s/ Karim Galzahr   Director   October 31, 2025
    Karim Galzahr        
             
    /s/ Olivier R. Jarry   Director   October 31, 2025
    Olivier R. Jarry        
             
    /s/ Theodore F. Search, Pharm.D.   Director   October 31, 2025
    Theodore F. Search, Pharm.D.        

     

    II-6

     

    Get the next $OSTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Former 10% Owner Auerbach Shalom

    4 - OS Therapies Inc (0001795091) (Issuer)

    5/9/25 9:45:04 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Auerbach Shalom sold $163,918 worth of shares (82,000 units at $2.00) (SEC Form 4)

    4 - OS Therapies Inc (0001795091) (Issuer)

    5/9/25 9:30:13 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Auerbach Shalom sold $81,566 worth of shares (60,012 units at $1.36) (SEC Form 4)

    4 - OS Therapies Inc (0001795091) (Issuer)

    4/11/25 9:45:07 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on OS Therapies with a new price target

    Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

    4/2/25 8:01:55 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

    New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced additional overall and event free survival data generated from the Company's 41-patient Phase 2b clinical trial of its off-the-shelf immunotherapeutic candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma (the "Phase 2b Osteosarcoma Trial"). The Company previously announced statistically significant positive final 2-year overall survival data from its Phase 2b Osteosarcoma Trial on October 10, 2025. The Company performed these subgroup ana

    10/22/25 9:15:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

    Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma dataNew York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that the United States Food & Drug Administration ("FDA") has granted a second Type C Meeting, following its successful End of Phase 2 Meeting. The primary purpose of the meeting is to gain alignment on the clinical efficacy data endpoints to support

    10/17/25 9:15:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

    75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year overall survivalNew York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the Company's Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma (the "Fu

    10/10/25 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    View All

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

    Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

    1/29/25 9:22:00 AM ET
    $ADXS
    $OSTX
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $OSTX
    Financials

    Live finance-specific insights

    View All

    OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

    75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year overall survivalNew York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the Company's Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma (the "Fu

    10/10/25 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

    New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025.About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initia

    8/14/25 5:44:00 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

    Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation requests Completed Phase 2b trial data analysis using methods agreed to by FDA to be presented at MIB Factor on June 28, 2025 Company remains on track for Q3 2025 BLA filing for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial res

    5/16/25 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OS Therapies Incorporated

    SC 13G - OS Therapies Inc (0001795091) (Subject)

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    SEC Filings

    View All

    SEC Form S-8 filed by OS Therapies Incorporated

    S-8 - OS Therapies Inc (0001795091) (Filer)

    10/31/25 4:37:31 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - OS Therapies Inc (0001795091) (Filer)

    10/21/25 4:16:01 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by OS Therapies Incorporated

    DEFA14A - OS Therapies Inc (0001795091) (Filer)

    10/17/25 5:08:54 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care